NCT01014806View on ClinicalTrials.gov

Evaluate the Safety and Immunogenicity of a Seasonal Influenza Virus-Like Particle (VLP) Vaccine in Older Adults

PHASE2CompletedINTERVENTIONAL
Enrollment

467

Participants

Timeline

Start Date

November 30, 2009

Primary Completion Date

May 31, 2010

Study Completion Date

May 31, 2010

Conditions
Influenza
Interventions
BIOLOGICAL

Influenza VLP Vaccine

Single dose; 0.5mL

BIOLOGICAL

TIV

Trivalent Influenza Vaccine 15ug/strain, commercially licensed

Trial Locations (6)

29464

Coastal Carolina Research Center, Mt. Pleasant

33024

Universtity Clinical Research, Pembroke Pines

55905

Mayo Clinic, Rochester

75234

Research Across America, Dallas

78229

Clinical Trials of Texas, Inc., San Antonio

02908

Brown University, Providence

Sponsors

Lead Sponsor

Novavax
All Listed Sponsors
lead

Novavax

INDUSTRY

NCT01014806 - Evaluate the Safety and Immunogenicity of a Seasonal Influenza Virus-Like Particle (VLP) Vaccine in Older Adults | Biotech Hunter | Biotech Hunter